(Q24236594)

2

0 references

author name string

Daria J Butters

1

0 references

Steven J Kirk

4

0 references

Peter T Mallon

Cochrane Database of Systematic Reviews

5

0 references

publication date

10 November 2010

0 references

published in

0 references

cites work

Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Adriamycin plus alkylating agents in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Single agent versus combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Taxane containing regimens for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Chemotherapy: what progress in the last 5 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Antitumour antibiotic containing regimens for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003368.PUB3

Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer

21 January 2018

1 reference

12 December 2020

An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer

1 reference

12 December 2020

Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer

1 reference

12 December 2020

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281

1 reference

12 December 2020

Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer

1 reference

12 December 2020

Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.

1 reference

12 December 2020

A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study

1 reference

12 December 2020

A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer

1 reference

12 December 2020

Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and pred

1 reference

12 December 2020

A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

1 reference

12 December 2020

An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine

1 reference

12 December 2020

The polychemotherapeutic treatment of advanced breast cancer

1 reference

12 December 2020

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and

1 reference

12 December 2020

A clinical trial of homoharringtonine in the treatment of advanced breast cancer.

1 reference

12 December 2020

Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer

1 reference

12 December 2020

Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer

1 reference

12 December 2020

Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

1 reference

12 December 2020

Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes

1 reference

12 December 2020

[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].

1 reference

12 December 2020

Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer

1 reference

12 December 2020

A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer

1 reference

12 December 2020

Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B

1 reference

12 December 2020

Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer

1 reference

12 December 2020

Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study

1 reference

12 December 2020

Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial

1 reference

12 December 2020

10.1002/14651858.CD003368.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21069675

1 reference

Consolidated OpenCitations Corpus – April 2017